Jing S Wen

US Patent:

20220339251, Oct 27, 2022

Filed:

Dec 3, 2021

Appl. No.:

17/542108

Inventors:

- Culver City CA, US
Jing Wen - Culver City CA, US

International Classification:

A61K 38/18
C12N 15/62
C12N 15/85
A61K 47/69
A61P 25/02
A61K 9/127
C07K 17/02
A61P 25/28
C07K 14/48

Abstract:

The present application provides nerve growth factor (NGF) variants with improved in vivo stability, methods for producing and purifying NGF variants, as well as potential therapeutic applications.

US Patent:

20220175957, Jun 9, 2022

Filed:

Feb 19, 2020

Appl. No.:

17/425857

Inventors:

- Oakland CA, US
Irvin S.Y. Chen - Palos Verdes Estates CA, US
Yunfeng Lu - Culver City CA, US
Jing Wen - Culver City CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 47/69
A61K 45/06
A61K 47/58
A61K 47/62
A61K 9/51
C07K 14/52

Abstract:

CNS metastases are a major cause of cancer deaths with few therapeutic options for treatment. Monoclonal anti-body-based therapy is one of the most successful therapeutic strategies for cancer; however, its efficacy is limited against CNS metastases due to insufficient CNS delivery. Here, we show significantly improved antibody delivery to the CNS using novel timed-release nanocapsules that encapsulate individual antibodies within a crosslinked phosphorylcholine polymer and gradually release cargo through hydrolysable crosslinkers. A single course of rituximab (RTX) nanocapsule treatment elevates RTX levels in the CNS by nearly 10-fold compared to native RTX. We improved control of CNS metastases in a murine xenograft model of non-Hodgkin lymphoma; moreover, using a xenograft humanized BLT mouse model, lymphomas were eliminated with a single course of RTX nanocapsule treatment. This approach is useful for treatment of cancers with CNS metastases and is generalizable for delivery of any antibody to the CNS.

US Patent:

20200397712, Dec 24, 2020

Filed:

Feb 24, 2020

Appl. No.:

16/799536

Inventors:

- Oakland CA, US
Irvin S.Y. CHEN - Palos Veerdes Estate CA, US
Ming YAN - Encino CA, US
Min LIANG - Encino CA, US
Masakazu KAMATA - Los Angeles CA, US
Jing WEN - Culver City CA, US

International Classification:

A61K 9/51
A61K 47/69
C12N 15/11
A61K 31/7105
C12N 15/87
A61K 31/713
A61K 47/14
A61K 47/18
A61K 47/20
A61K 47/22
A61K 47/42

Abstract:

Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.

US Patent:

20200323786, Oct 15, 2020

Filed:

May 24, 2017

Appl. No.:

16/304116

Inventors:

- Oakland CA, US
- Los Angeles CA, US
- Tianjin, CN
Juanjuan Du - San Diego CA, US
Jing Wen - Culver City CA, US
Yang Liu - Los Angeles CA, US
Xubo Yuan - Tianjin, CN

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
THE UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA
TIANJIN UNIVERSITY - Tianjin CA

International Classification:

A61K 9/51
A61K 38/18
B82Y 5/00
A61P 19/00

Abstract:

Growth factors are of great potential in regenerative medicine. However, their clinical applications are largely limited in by short in vivo half-lives and a narrow therapeutic window. Thus, a robust controlled release system remains an unmet medical need for growth-factor-based therapies. A nanoscale controlled release system (degradable protein nanocapsule) is provided via in-situ polymerization on growth factor. The release rate can be finely tuned by engineering the surface polymer composition. Improved therapeutic outcomes are achieved with the growth factor nanocapsules, as illustrated in spinal cord fusion mediated by bone morphogenetic protein-2 (BMP-2) nanocapsules.

US Patent:

20190330636, Oct 31, 2019

Filed:

Dec 29, 2017

Appl. No.:

16/475294

Inventors:

- Cheyenne WY, US
Jing Wen - Culver City CA, US

International Classification:

C12N 15/113
A61K 9/51
A61K 45/06
A61P 9/10
A61K 31/7105

Abstract:

Provided herein are novel methods of treating cerebral ischemia, comprising administering a polymer nanocapsule or a composition thereof. Said nanocapsules comprise a polymer shell and an RNAi (e.g., miRNA) molecule, wherein the polymer shell comprises a) at least one positively charged monomer, b) at least one degradable cross-linker, and c) at least one neutral monomer; and the RNAi molecule provides therapeutic benefits to a subject suffering from cerebral ischemia. Also disclosed herein are compositions of said polymer nanocapsules.

US Patent:

20180369159, Dec 27, 2018

Filed:

Dec 14, 2016

Appl. No.:

16/063221

Inventors:

- Oakland CA, US
Jie LI - Los Angeles CA, US
Yang LIU - Los Angeles CA, US
Jie REN - Los Angeles CA, US
Jing WEN - Culver City CA, US

International Classification:

A61K 9/51
A61K 38/38

Abstract:

The invention relates to protein nanocapsules that exhibit material properties that change in different in vivo environments. A zwitterion moiety on the surface of the nanocapsule can protect the protein from opsonization in a first environment, yet uncouples from the protein nanocapsule in a second environment (e.g. at a pH of less than 6.5). In embodiments of the invention, the uncoupled protein nanocarrier is then internalized by mammalian cells (e.g. tumor cells).

US Patent:

20180235898, Aug 23, 2018

Filed:

Apr 24, 2018

Appl. No.:

15/961407

Inventors:

- Oakland CA, US
Tatiana Segura - Los Angeles CA, US
Suwei Zhu - Los Angeles CA, US
Jing Wen - Culver City CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 9/51
A61K 47/65
A61K 9/19
A61K 38/18

Abstract:

The invention provides methods of making and using compositions comprising a polymer shell designed to deliver polypeptides to selected environments. In embodiments of the invention, different environmental conditions are harnessed to allow the selective degradation of the polymer shell and the consequential release of one or polypeptides encapsulated therein. In illustrative embodiments, polymer components of the shell are interconnected by peptide-containing crosslinker to moieties, linkages which maintain the integrity of the polymer shell under certain enviromental conditions, but can also be cleaved when combined with a selected protease.

US Patent:

20180236031, Aug 23, 2018

Filed:

Feb 9, 2018

Appl. No.:

15/892527

Inventors:

- Culver City CA, US
Jing Wen - Culver City CA, US

International Classification:

A61K 38/18
C12N 15/62
C12N 15/85
A61P 25/28
A61P 25/02
A61K 9/127
C07K 17/02
A61K 47/69

Abstract:

The present application provides nerve growth factor (NGF) variants with improved in vivo stability, methods for producing and purifying NGF variants, as well as potential therapeutic applications.